Successful Management of Neutropenic Sepsis Is Key to Better Survival of Patients With Blood Cancer in Sri Lanka: Real-World Data From the Resource-Limited Setting Myelodysplastic syndromes (MDS) ...
Molecular lesion data in LR-MDS prognostic models reduce the significance of traditional parameters like bone marrow blast percentage. Molecular data altered risk stratification for 30% of patients, ...
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as ...
Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).
MNV-201 has received orphan drug designation for myelodysplastic syndrome, offering regulatory and financial benefits to encourage its development. The therapy uses Mitochondrial Augmentation ...
Bexmarilimab and Vidaza achieved high response rates in higher-risk myelodysplastic syndrome, meeting the phase 2 BEXMAB trial's primary endpoint. The treatment demonstrated a 63% objective response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results